ADIL Stock Catalyst: Adial Pharmaceuticals Granted New U.S. Patent for Genetic-Based Treatment Method

Apr 30, 2025 · 3:55pm ET

The patent covers a treatment method for alcohol and opioid use disorders.

Max move

+34.1%

High of day $23.25

Sparker timei

3:55pm ET

ADIL · Apr 30, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Adial Pharmaceuticals, Inc. (ADIL) announced on May 1, 2025, that it has been granted a new U.S. patent by the United States Patent and Trademark Office. The patent is for a genetic-based treatment method aimed at addressing alcohol and opioid use disorders.

This development signifies a significant advancement in Adial Pharmaceuticals' research and development efforts within the biotechnology sector. The company's free float stands at 23,878,900 shares, with 26,649,600 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time ADIL sparks.

Download Sniper App →

Catch the next ADIL-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →